Supplementary materials: Cost–effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure' published in the Journal of Comparative Effectiveness Research.Supplemental Table 1: Full table of inputsSupplemental Table 2: Results of scenario analysesSupplemental Figure 1: Survival curve, sotagliflozin vs. SoC groupsSupplemental Figure 2: Tornado diagramAim: To assesses the cost–effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes. Materials & methods: A de novo cost–effectiveness model with a Markov structure was created for patients hospitalized for heart failure with comorbid diabetes. Outcomes of interest included hospital readmissions, emergency department visits and all-cause mortality measured over a 30-year time horizon. Baseline event frequencies were derived from published real-world data studies; sotagliflozin’s efficacy was estimated from SOLOIST-WHF. Health benefits were calculated quality-adjusted life years (QALYs). Costs included pharmaceutical costs, rehospitalization, emergency room visits and adverse events. Economic value was measured using the incremental cost–effectiveness ratio (ICER). Results: Sotagliflozin use decreased annualized rehospitalization rates by 34.5% (0.228 vs 0.348, difference: -0.120), annualized emergency department visits by 40.0% (0.091 vs 0.153, difference: -0.061) and annualized mortality by 18.0% (0.298 vs 0.363, difference: -0.065) relative to standard of care, resulting in a net gain in QAYs of 0.425 for sotagliflozin versus standard of care. Incremental costs using sotagliflozin increased by $19,374 over a 30-year time horizon of the patient, driven largely by increased pharmaceutical cost. Estimated ICER for sotagliflozin relative to standard of care was $45,596 per QALY. Conclusion: Sotagliflozin is a cost-effective addition to standard of care for patients hospitalized with heart failure and comorbid diabetes.

本数据集为发表于《比较效果研究杂志》之文章《索他格列呋在治疗合并近期恶化心力衰竭的糖尿病患者中的成本效益》的同行评审补充材料。补充表1：输入参数完整表格；补充表2：情景分析结果；补充图1：生存曲线，索他格列呋组与标准治疗方案组对比；补充图2：风车图。研究目的：评估索他格列呋治疗住院合并心力衰竭及糖尿病患者的成本效益。研究方法：为治疗住院合并心力衰竭的糖尿病患者构建了一个全新成本效益模型，具有马尔可夫结构。关注的结局包括住院再入院、急诊科就诊和全因死亡率，测量时间为30年。基线事件频率来源于已发表的实地数据研究；索他格列呋的疗效从SOLOIST-WHF研究中估算。健康效益以质量调整生命年（QALYs）计算。成本包括药品费用、再住院、急诊科就诊和不良事件。经济价值通过增量成本效益比（ICER）衡量。研究结果：与标准治疗方案相比，索他格列呋的使用降低了年化再入院率34.5%（0.228 vs 0.348，差异：-0.120）、年化急诊科就诊率40.0%（0.091 vs 0.153，差异：-0.061）和年化死亡率18.0%（0.298 vs 0.363，差异：-0.065），导致索他格列呋相对于标准治疗方案净增加0.425个QALY。在30年的患者时间范围内，使用索他格列呋的增量成本增加了19,374美元，主要由药品费用增加驱动。索他格列呋相对于标准治疗方案的估计ICER为每QALY 45,596美元。结论：索他格列呋是标准治疗方案中治疗住院合并心力衰竭及糖尿病患者的经济有效补充。